Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX007 in LC-FAOD
NCT01886378Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Feb 2014
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of triheptanoin in Long Chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical Inc.. Started Feb 2014; status: completed.
02
Drugs
triheptanoin
03
Conditions
Long Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Beyond the preview
Go deeper on NCT01886378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01886378.